Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Nakamura, Ryota; Yamada, Tadaaki; Tokuda, Shinsaku; Morimoto, Kenji; Katayama, Yuki; Matsui, Yohei; Hirai, Soichi; Ishida, Masaki; Kawachi, Hayato; Sawada, Ryo; Tachibana, Yusuke; Osoegawa, Atsushi; Horinaka, Mano; Sakai, Toshiyuki; Yasuhiro, Tomoko; Kozaki, Ryohei; Yano, Seiji; Takayama, Koichi

doi:10.1016/j.canlet.2024.217124

Cancer Letters

2024

DOI: 10.1016/j.canlet.2024.217124

|View full text |Cite

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Ryota Nakamura,

Tadaaki Yamada,

Shinsaku Tokuda

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2025

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Wu,

Sun,

Tang

et al. 2025

Drug Resistance Updates

View full text Add to dashboard Cite

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Wu,

Sun,

Tang

et al. 2025

Drug Resistance Updates

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer

Cited by 1 publication

References 42 publications

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Contact Info

Product

Resources

About